Core Viewpoint - TransCode Therapeutics has adjourned its Special Meeting originally scheduled for February 4, 2025, to February 25, 2025, to solicit additional votes on key proposals related to the issuance of shares and adjustments to warrants [1][3]. Group 1: Special Meeting Details - The Special Meeting was adjourned due to a lack of quorum, with only approximately 29.94% of the outstanding shares represented [2]. - The Adjourned Special Meeting will be held virtually, allowing stockholders to participate and vote online [3]. - Stockholders are encouraged to vote their shares by February 24, 2025, at 11:59 p.m. Eastern time [4][9]. Group 2: Proposals Overview - Proposal One seeks approval for the full issuance of shares of Common Stock upon the exercise of Series C and Series D Warrants, including adjustments to the exercise price and an alternative cashless exercise feature [6]. - Proposal Two is to adjourn the Special Meeting to allow further solicitation of proxies if there are insufficient votes for Proposal One [6]. Group 3: Voting Instructions - Stockholders can vote by mail, online, or by telephone, with all votes needing to be received by February 24, 2025, to be counted [7][14]. - Those who have already voted and do not wish to change their vote need not take any action [5]. Group 4: Company Overview - TransCode Therapeutics is focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [10]. - The lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [10]. - The company has a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges [10].
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting